GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Cyclically Adjusted Revenue per Share

CARA (Cara Therapeutics) Cyclically Adjusted Revenue per Share : $28.91 (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cara Therapeutics's adjusted revenue per share for the three months ended in Dec. 2024 was $0.955. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $28.91 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Cara Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-13), Cara Therapeutics's current stock price is $15.96. Cara Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was $28.91. Cara Therapeutics's Cyclically Adjusted PS Ratio of today is 0.55.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cara Therapeutics was 12.01. The lowest was 0.31. And the median was 1.34.


Cara Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Cara Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Cyclically Adjusted Revenue per Share Chart

Cara Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 37.31 28.36 28.91

Cara Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.36 28.98 28.98 29.00 28.91

Competitive Comparison of Cara Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Cara Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cara Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

Cara Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cara Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.955/133.1571*133.1571
=0.955

Current CPI (Dec. 2024) = 133.1571.

Cara Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.771 99.621 1.031
201506 1.379 100.684 1.824
201509 3.437 100.392 4.559
201512 0.000 99.792 0.000
201603 0.009 100.470 0.012
201606 0.104 101.688 0.136
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 1.202 102.862 1.556
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 3.107 106.317 3.891
201809 4.789 106.507 5.987
201812 5.044 105.998 6.336
201903 3.987 107.251 4.950
201906 4.709 108.070 5.802
201909 4.677 108.329 5.749
201912 3.475 108.420 4.268
202003 6.235 108.902 7.624
202006 4.334 108.767 5.306
202009 7.117 109.815 8.630
202012 78.714 109.897 95.374
202103 1.395 111.754 1.662
202106 0.000 114.631 0.000
202109 14.563 115.734 16.755
202112 0.560 117.630 0.634
202203 3.223 121.301 3.538
202206 15.449 125.017 16.455
202209 7.247 125.227 7.706
202212 2.184 125.222 2.322
202303 4.121 127.348 4.309
202306 4.622 128.729 4.781
202309 3.229 129.860 3.311
202312 1.985 129.419 2.042
202403 1.408 131.776 1.423
202406 0.652 132.554 0.655
202409 1.678 133.029 1.680
202412 0.955 133.157 0.955

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Cara Therapeutics  (NAS:CARA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cara Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=15.96/28.91
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cara Therapeutics was 12.01. The lowest was 0.31. And the median was 1.34.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cara Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Executives
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Joana Goncalves officer: Chief Medical Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion officer: Sec'y; Chief Compliance & G.C. C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Menzaghi Frederique Ph.d. officer: VP-Research & Development C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ryan D Maynard officer: Chief Financial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Moltke Lisa Von director C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum director 675 ALMANOR AVE, SUNNYVALE CA 94085
Csl Ltd 10 percent owner
Jeffrey L. Ives director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr director
Thomas Charles Reilly officer: Chief Financial Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd. 10 percent owner RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027